Vertex Days Sales Outstanding from 2010 to 2025

VRTX Stock  USD 498.96  3.59  0.71%   
Vertex Pharmaceuticals Days Sales Outstanding yearly trend continues to be fairly stable with very little volatility. Days Sales Outstanding is likely to outpace its year average in 2025. During the period from 2010 to 2025, Vertex Pharmaceuticals Days Sales Outstanding regression line of annual values had r-squared of  0.36 and arithmetic mean of  49.83. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
53.30541465
Current Value
58.29
Quarterly Volatility
10.78986882
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 11.6 B, Gross Profit of 10 B or Other Operating Expenses of 11.8 B, as well as many indicators such as Price To Sales Ratio of 8.94, Dividend Yield of 0.0 or PTB Ratio of 7.39. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Slightly volatile
   Days Sales Outstanding   
       Timeline  

Vertex Days Sales Outstanding Regression Statistics

Arithmetic Mean49.83
Geometric Mean48.53
Coefficient Of Variation21.66
Mean Deviation8.29
Median53.31
Standard Deviation10.79
Sample Variance116.42
Range40.9
R-Value0.60
Mean Square Error80.08
R-Squared0.36
Significance0.01
Slope1.36
Total Sum of Squares1,746

Vertex Days Sales Outstanding History

2025 58.29
2024 53.31
2023 57.82
2022 58.94
2021 54.78
2020 52.07
2019 55.55

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Days Sales Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Sales Outstanding 53.31  58.29 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.